← Leaderboards
Carlos A Casiano
Loma Linda University
$2,301,216
Attributed
$2,781,578
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $343.8K · FY2005–25$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,781,578 · 6
By mechanism
P20$1,103,421 · 2
R21$1,050,010 · 2
R29$383,041 · 1
T32$245,106 · 1
Top collaborators
- Frankie G Almaguel4 shared
- Bhaskar Chandra Das4 shared
- Marino De Leon1 shared
Most similar at Loma Linda University
Same institution · by research overlap
- Frankie G Almaguel$178,904
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorProteinsDesignMalignant Neoplasm Of ProstateProstate Cancer CellRacial DisparityMortalityAutoantibodiesTumor AntigensPilot ProjectsMolecularAfrican AmericanMortality DisparityNew Therapeutic TargetMalignant NeoplasmsHealth DisparityCancer Health DisparityInnovationDisease ProgressionAffectCancer PatientBiological MarkersDiagnosticGenes
Grant awards (17)
Initiative for Maximizing Student Development at Loma Linda University$245,106
T32 · FY2025 · GM
Role and Theranostics Potential of Enolase in Prostate Cancer Health Disparities$212,181
R21 · FY2024 · CA · contact PI
Role and Theranostics Potential of Enolase in Prostate Cancer Health Disparities$74,406
R21 · FY2024 · CA · contact PI
Role and Theranostics Potential of Enolase in Prostate Cancer Health Disparities$186,539
R21 · FY2023 · CA · contact PI
Administrative Diversity Supplement to: "Role and Theranostics Potential of Enolase in Prostate Cancer Health Disparities"$63,587
R21 · FY2023 · CA · contact PI
Glucocorticoid signaling, taxane resistance, and prostate cancer mortality disparity$280,306
R21 · FY2020 · CA · contact PI
Glucocorticoid signaling, taxane resistance, and prostate cancer mortality disparity$171,825
R21 · FY2019 · CA · contact PI
Glucocorticoid signaling, taxane resistance, and prostate cancer mortality disparity$61,166
R21 · FY2019 · CA · contact PI
Immunoseroproteomics in Prostate Cancer: Focus on Health Disparities$163,681
P20 · FY2016 · MD · contact PI
Immunoseroproteomics in Prostate Cancer: Focus on Health Disparities$167,347
P20 · FY2015 · MD · contact PI
Immunoseroproteomics in Prostate Cancer: Focus on Health Disparities$154,053
P20 · FY2014 · MD · contact PI
Immunoseroproteomics in Prostate Cancer: Focus on Health Disparities$82,470
P20 · FY2013 · MD · contact PI
Immunoseroproteomics in Prostate Cancer: Focus on Health Disparities$192,116
P20 · FY2012 · MD · contact PI
RESEARCH EDUCATION AND TRAINING CORE$343,754
P20 · FY2005 · MD
AUTOANTIGEN CLEAVAGE DURING APOPTOSIS AND NECROSIS$134,572
R29 · FY2002 · AI
AUTOANTIGEN CLEAVAGE DURING APOPTOSIS AND NECROSIS$126,638
R29 · FY2001 · AI
AUTOANTIGEN CLEAVAGE DURING APOPTOSIS AND NECROSIS$121,831
R29 · FY2000 · AI